StockNews.com Upgrades Kura Oncology (NASDAQ:KURA) to “Hold”

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a hold rating in a report released on Tuesday morning.

Several other equities analysts also recently weighed in on KURA. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday, November 6th. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Trading Down 3.5 %

Shares of KURA opened at $15.92 on Tuesday. The firm’s 50-day moving average is $18.50 and its two-hundred day moving average is $19.92. Kura Oncology has a twelve month low of $8.80 and a twelve month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.24 billion, a P/E ratio of -6.75 and a beta of 0.86.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. nVerses Capital LLC bought a new stake in shares of Kura Oncology in the third quarter worth $25,000. ProShare Advisors LLC raised its stake in shares of Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of Kura Oncology by 2.4% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after purchasing an additional 1,673 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Hsbc Holdings PLC grew its stake in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.